Filip K Knop
Filip K Knop
Director, Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Denmark
Verified email at dadlnet.dk
TitleCited byYear
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud
Bmj 344, d7771, 2012
7142012
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ...
Diabetes 56 (8), 1951-1959, 2007
3532007
Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity
A Vrieze, C Out, S Fuentes, L Jonker, I Reuling, RS Kootte, E van Nood, ...
Journal of hepatology 60 (4), 824-831, 2014
2852014
Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with …
PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ...
Diabetologia 52 (2), 199, 2009
2762009
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide—regardless of …
T Vilsbøll, FK Knop, T Krarup, A Johansen, S Madsbad, S Larsen, ...
The Journal of Clinical Endocrinology & Metabolism 88 (10), 4897-4903, 2003
2232003
The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action
KJ Hare, T Vilsbøll, M Asmar, CF Deacon, FK Knop, JJ Holst
Diabetes 59 (7), 1765-1770, 2010
2092010
Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes
JJ Holst, FK Knop, T Vilsbøll, T Krarup, S Madsbad
Diabetes Care 34 (Supplement 2), S251-S257, 2011
2072011
Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
S Calanna, M Christensen, JJ Holst, B Laferrere, LL Gluud, T Vilsbøll, ...
Diabetologia 56 (5), 965-972, 2013
1972013
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop
Diabetes 60 (12), 3103-3109, 2011
1962011
Impaired regulation of the incretin effect in patients with type 2 diabetes
JI Bagger, FK Knop, A Lund, H Vestergaard, JJ Holst, T Vilsbøll
The Journal of Clinical Endocrinology & Metabolism 96 (3), 737-745, 2011
1922011
2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans
KB Hansen, MM Rosenkilde, FK Knop, N Wellner, TA Diep, JF Rehfeld, ...
The Journal of Clinical Endocrinology & Metabolism 96 (9), E1409-E1417, 2011
1892011
Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center
S Meisner, M Hensler, FK Knop, F West, P Wille-Jørgensen
Diseases of the colon & rectum 47 (4), 444-450, 2004
1642004
The Nkx6. 1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells
JC Schisler, PB Jensen, DG Taylor, TC Becker, FK Knop, S Takekawa, ...
Proceedings of the National Academy of Sciences 102 (20), 7297-7302, 2005
1632005
Inappropriate suppression of glucagon during OGTT but not during isoglycaemic iv glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus
FK Knop, T Vilsbøll, S Madsbad, JJ Holst, T Krarup
Diabetologia 50 (4), 797-805, 2007
1452007
Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition
RS Kootte, E Levin, J Salojärvi, LP Smits, AV Hartstra, SD Udayappan, ...
Cell metabolism 26 (4), 611-619. e6, 2017
1392017
Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
FK Knop, K Aaboe, T Vilsbøll, A Vølund, JJ Holst, T Krarup, S Madsbad
Diabetes, Obesity and Metabolism 14 (6), 500-510, 2012
1362012
The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
A Lund, T Vilsbøll, JI Bagger, JJ Holst, FK Knop
American Journal of Physiology-Endocrinology and Metabolism 300 (6), E1038-E1046, 2011
1342011
Regulation of glucagon secretion by incretins
JJ Holst, M Christensen, A Lund, J De Heer, B Svendsen, U Kielgast, ...
Diabetes, Obesity and Metabolism 13, 89-94, 2011
1292011
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities
A Lund, FK Knop, T Vilsbøll
European journal of internal medicine 25 (5), 407-414, 2014
1212014
Twelve weeks treatment with the DPP‐4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non‐glucose induced insulin secretion in patients with …
K Aaboe, FK Knop, T Vilsbøll, CF Deacon, JJ Holst, S Madsbad, T Krarup
Diabetes, Obesity and Metabolism 12 (4), 323-333, 2010
1112010
The system can't perform the operation now. Try again later.
Articles 1–20